← Back to Search

Anticoagulant

Bivalirudin vs Heparin for Coronary Artery Disease

Phase 4
Waitlist Available
Led By Herman K Gold, MD
Research Sponsored by Gold, Herman K., MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of angina pectoris defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia
Patients must be >18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing whether bivalirudin, a blood thinner, plus a second medication is better than heparin plus a different second medication at preventing vascular complications in people undergoing a heart procedure.

Who is the study for?
This trial is for adults over 18 with coronary heart disease needing angioplasty or stenting. They must have angina, unstable angina, or silent ischemia and agree to follow-up evaluations. Excluded are those with certain blood conditions, recent severe heart attacks, end-stage kidney disease, on conflicting medications, pregnant women or those who might become pregnant without a negative pregnancy test.Check my eligibility
What is being tested?
The study compares two treatments in patients having percutaneous coronary intervention (PCI): one group receives bivalirudin with provisional Gp IIB/IIIA inhibitors; the other gets heparin plus Gp IIB/IIIA inhibitor eptifibatide. The goal is to see which treatment leads to fewer vascular complications.See study design
What are the potential side effects?
Possible side effects include bleeding risks, allergic reactions to the drugs used (bivalirudin or eptifibatide), and potential issues related to intravenous drug administration like bruising at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with chest pain due to heart issues or silent heart disease.
Select...
I am older than 18 years.
Select...
I have been referred for a procedure to open blocked arteries in my heart.
Select...
I need a procedure to open blocked arteries in my heart.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients who require a vascular groin ultrasound or abdominal CT.
Record hemoglobin drop >3g/dl with over bleeding. Also, record any red cell transfusion due to catheterization related bleeding.
Record occurrence of pseudoaneurysm, arteriovenous fistula, retroperitoneal hematoma, or femoral vein or arterial thrombosis
+1 more
Secondary outcome measures
Comparison of time to ambulation.
Observe incidence of thrombocytopenia post catheterization defined as a platelet count <100,000.
Occurrence of major and minor bleeding peri-catheterization.

Find a Location

Who is running the clinical trial?

Gold, Herman K., MDLead Sponsor
1 Previous Clinical Trials
120 Total Patients Enrolled
1 Trials studying Coronary Artery Disease
120 Patients Enrolled for Coronary Artery Disease
The Medicines CompanyIndustry Sponsor
71 Previous Clinical Trials
77,655 Total Patients Enrolled
6 Trials studying Coronary Artery Disease
16,190 Patients Enrolled for Coronary Artery Disease
Herman K Gold, MDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
120 Total Patients Enrolled
1 Trials studying Coronary Artery Disease
120 Patients Enrolled for Coronary Artery Disease

Media Library

Bivalirudin (Anticoagulant) Clinical Trial Eligibility Overview. Trial Name: NCT00476944 — Phase 4
Coronary Artery Disease Research Study Groups:
Coronary Artery Disease Clinical Trial 2023: Bivalirudin Highlights & Side Effects. Trial Name: NCT00476944 — Phase 4
Bivalirudin (Anticoagulant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00476944 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to take part in this investigation?

"Sadly, this clinical trial is not recruiting any more participants. The research was initially posted on September 1st 2006 and last revised May 18th 2007. Nonetheless, 571 other studies are presently advertising for volunteers in the present day."

Answered by AI

How hazardous is this medication for individuals?

"The safety rating of this treatment was determined to be a 3 due to its Phase 4 status, which reflects the fact that it has completed rigorous testing and been officially approved."

Answered by AI
~19 spots leftby Mar 2025